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Abstract
Background: Malignant glioma cells are particularly motile and can travel diffusely through the
brain parenchyma, apparently without following anatomical structures to guide their migration. The
neural adhesion/recognition protein L1 (L1CAM; CD171) has been implicated in contributing to
stimulation of motility and metastasis of several non-neural cancer types. We explored the
expression and function of L1 protein as a stimulator of glioma cell motility using human high-grade
glioma surgical specimens and established rat and human glioma cell lines.
Results: L1 protein expression was found in 17 out of 18 human high-grade glioma surgical
specimens by western blotting. L1 mRNA was found to be present in human U-87/LacZ and rat C6
and 9L glioma cell lines. The glioma cell lines were negative for surface full length L1 by flow
cytometry and high resolution immunocytochemistry of live cells. However, fixed and
permeablized cells exhibited positive staining as numerous intracellular puncta. Western blots of
cell line extracts revealed L1 proteolysis into a large soluble ectodomain (~180 kDa) and a smaller
transmembrane proteolytic fragment (~32 kDa). Exosomal vesicles released by the glioma cell lines
were purified and contained both full-length L1 and the proteolyzed transmembrane fragment.
Glioma cell lines expressed L1-binding αvβ5 integrin cell surface receptors. Quantitative time-lapse
analyses showed that motility was reduced significantly in glioma cell lines by 1) infection with an
antisense-L1 retroviral vector and 2) L1 ectodomain-binding antibodies.
Conclusion: Our novel results support a model of autocrine/paracrine stimulation of cell motility
in glioma cells by a cleaved L1 ectodomain and/or released exosomal vesicles containing L1. This
mechanism could explain the diffuse migratory behavior of high-grade glioma cancer cells within the
brain.
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Background
Malignant gliomas are brain cancers that are particularly
insidious because of their extremely invasive behavior and
are lethal mostly because of their rapid spreading in the
brain [1,2]. They often follow existing anatomical struc-
tures such as nerve fiber tracts and blood vessels, but gli-
oma cells also can migrate diffusely through the neuropil
(i.e. diffuse glioma). Diffuse migration as single cells or
small groups is a primary reason for therapeutic failure,
and there are no imaging techniques available that can
detect such diffuse migration. The mechanisms by which
glioma cell invasion occur are poorly understood.
Recently, many researchers have uncovered alterations in
gene expression at different stages of malignant transfor-
mation of these cells. It is now important to identify
which of these or other changes are related to glioma inva-
siveness and to what extent experimental alterations in
expression of specific genes govern this important feature
[3]. The neural cell adhesion/recognition protein L1
(L1CAM; CD171) is abnormally expressed in multiple
cancer cell types, including high-grade gliomas [4].
Whereas L1 is not expressed in normal tissues from which
the cancer cells arise [5], it has been implicated in motility
and metastasis in some malignant cancers [6,7].
L1 is a 200-220 kDa type I membrane glycoprotein
belonging to the immunoglobulin superfamily that con-
tains six immunoglobulin-like domains (Ig domains),
five fibronectin-like repeats (FN repeats), a transmem-
brane domain, and a highly conserved cytoplasmic
domain [8,9]. L1 has homophilic (L1-L1) binding via sev-
eral Ig domains [10] and also has heterophilic interac-
tions with axonin-1 [11], CD24 [12], the proteoglycan
neurocan and several integrins [13]. The significance of
L1's function in central nervous system development is
well established, which includes facilitating neuronal
migration, neuronal survival, as well as axon outgrowth,
guidance, fasciculation and regeneration, [14-17]. Muta-
tions in the human L1 gene cause a myriad of nervous sys-
tem birth defects [18] such as Hydrocephalus due to
congenital Stenosis of Aqueduct of Sylvius (HSAS) and
MASA Syndrome. Although L1 was initially described in
the nervous system and thought to be restricted to post-
mitotic neurons in the adult central nervous system and
pre- and non-myelinating Schwann cells in the adult
peripheral nervous system [19,20], L1 expression is also
found in hematopoietic and some epithelial cells [21-24].
L1 has been demonstrated to be expressed in different
human cancers including lung cancer, glioma, melanoma,
renal carcinoma, and colon carcinoma [4,25-31]. Further-
more, L1 is suggested to be a new tumor marker in those
malignancies [5,32]. The expression of L1 in a variety of
cancer types suggests the potential role of L1 in tumor cell
adhesion and/or migration.
L1 is proteolyzed and released from the cell membrane by
ADAM10 and ADAM17, two members of the disintegrin
and metalloprotease (ADAM) family [33-37]. The soluble
L1 ectodomain, after ADAM mediated proteolysis, has
been suggested to interact with integrins to stimulate cell
motility and cell migration [33]. The Arg-Gly-Asp (RGD)
motif in the 6th Ig domain of L1 interacts with several
integrins including α5β1, αvβ3, αvβ5, αvβ1 as well as the
platelet integrin αIIbβ3 [38,22,39,40,13,33]. The soluble
L1 ectodomain has also been detected in serum samples
of patients with melanoma, ovarian and uterine tumors
and is suggested to increase cell migration and metastasis
in those cancers [28,41]. L1 and ADAM10 mediated L1
proteolysis also induces metastasis in human colon cancer
cells [37].
L1 is also released from melanoma and ovarian cancer
cells extracellularly in the form of exosomes and can be
cleaved by ADAMs within the exosomes [42,43]. Exo-
somes are minute membrane vesicles that are released
from a variety of cell types including tumor cells, red
blood cells, platelets, lymphocytes, and dendritic cells
[43,44] via the fusion of multivesicular endosomes with
the plasma membrane [45]. This suggests that exosomes
might be another source of "soluble" L1 ectodomain from
cancer cells in addition to that which occurs from ADAM
proteolysis.
Although the expression of L1 and its potential stimula-
tory function in glioma motility has been approached
[4,46-48], precise measurements of L1-mediated stimula-
tion have not been documented. Here, we hypothesized
that the soluble L1 ectodomain resulting from ADAM pro-
teolysis and/or L1-containing exosomes stimulate glioma
cell motility through integrins in an autocrine matter. We
demonstrated that gliomas express and cleave L1, release
exosomes containing L1, express receptors for L1, and gli-
oma cell motility is stimulated by L1.
Results
L1 is expressed in high-grade glioma surgical samples
Eighteen high-grade (III-IV) glioma surgical samples were
obtained as described in the methods. Such gliomas
express glial fibrillary acidic protein (GFAP) [49-51] and
are associated with high proliferation potential [52]. Here,
the glioma surgical samples were stained with GFAP and
Ki67 (a proliferation marker) to further confirm the iden-
tity and malignancy of the samples collected (Fig. 1A, B).
L1 expression was assessed in these samples in two ways.
Fourteen of the 18 surgical samples were directly lysed in
RIPA lysis buffer, followed by electrophoresis and western
blotting for L1 (Fig. 1C-E). Alternatively, cell cultures were
made from dissociated surgical samples and kept in cul-
ture for 2, 4, or 15 weeks, followed by dissociation, pro-
tein extraction, and western blotting (4 of the 18 samples,Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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Characterization of human primary glioma surgical samples Figure 1
Characterization of human primary glioma surgical samples. Extensive GFAP (A, left panel) expression was detected 
in primary glioma surgical sample frozen sections using immunofluorescent staining with a rabbit anti-GFAP antibody. (B, left 
panel) Numerous dividing cells were detected in the same surgical glioma sample using an anti-Ki67 antibody. Right panels in 
(A) and (B) are nuclear counterstaining for GFAP and Ki67 stained sections, respectively. (C) Demonstration of specificity of 
anti-L1 antibodies anti-cytoplasmic polyclonal NCAM-L1 (left panel) and anti-ectodomain monoclonal UJ127 (right panel) by 
western blot analysis. Human L1-expressing quail QT6 cells (QT6/hFL1) were used as positive controls (PC), untransfected 
QT6 cells were used as negative controls (NC), and plain QT6 cell culture media (M) was used as an additional negative con-
trol. (D) L1 expression was found in human primary gliomas surgical samples (sample numbers 10-15 and 17-20) by western 
blot analysis using UJ127 anti-L1 antibody. Transfected QT6/hFL1 cells were used as positive control and QT6 cells were used 
as a negative control. Gels were loaded with 10 μg total protein and probed for GAPDH as a loading control (see text). (E) 
Analysis of surgical samples 18-20 using anti-L1 antibody NCAM-L1. Same blot was used as for (D, right panel, 10 μg total pro-
tein/well). GAPDH was used as a loading control. (F) Analysis of glioma surgical samples for L1 protease ADAM10, revealing 
that all samples were positive predominantly for active ADAM10 (approx. 55 kDa). (G) Surgical samples # 7, 18, 19, and 20 
were analyzed by western blot with a rabbit anti-NF-M antibody to detect neurofilament expression. Adult rat brain (RB) 
lysate was used as a positive control for NF-M staining. (H) Media from surgical sample cells grown in culture were analyzed by 
western blot for L1. Soluble L1 was detectable in media from sample # 21. Positive controls (PC) were cell lysates from QT6/
hFL1 cells, and untransfected cell lysate was used as negative control (NC). Media from CHO cells transfected with an L1 ecto-
domain vector (CHO-L1ecto) were also used as a positive control for soluble L1. Media from untransfected CHO cells were 
used as a negative control.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
Page 4 of 17
(page number not for citation purposes)
data not shown). Seventeen of the 18 surgical samples
showed L1 expression regardless of whether they were a
fresh surgical sample or in culture for 2-15 weeks. L1
expression was variable (Fig. 1D; 10 μg/well), ranging
from high-level to barely detectable and was only non-
detectable in one sample (#19). The samples showed L1
expression by using either NCAM-L1 C-20 or UJ127 anti-
bodies as a high molecular weight form of approximately
220 kDa. A 32 kDa membrane bound proteolytic frag-
ment (the result of ADAM10 cleavage) was not found
using the NCAM-L1 antibody (Fig. 1E), specific for a cyto-
plasmic epitope of L1. This suggests that L1 has not been
proteolyzed in our surgical specimens, a phenomenon
which does occur in the surgical sample cells in culture
and in glioma cell lines (see below). Alternatively, the
cleavage that might occur in the surgical specimens may
occur at a level too low to visualize, or the 32 kDa cyto-
plasmic fragment might be cleaved by gamma-secretase
[35]. Nevertheless, our results demonstrate L1 expression
in the vast majority of our high-grade glioma samples
and, thus, L1 may play a functional role in these tumors.
We analyzed surgical samples for L1 protease ADAM10
[31,33] by western blotting to determine if the reason that
L1 was not proteolyzed in these samples was due to the
absence of the protease. ADAM10 was expressed in all
samples analyzed and primarily in its active lower molec-
ular weight form (Fig. 1F, approximately 55 kDa band),
even in sample 19 where L1 expression was not detected.
The higher molecular weight band present in sample #17
most likely represents the inactive ADAM10 precursor.
Thus, the lack of L1 proteolysis in surgical samples must
be due to something other than the lack of ADAM10
expression.
To analyze for the potential presence of neurons that
might contribute to the L1 that was detected above, a neu-
ronal marker was assessed in four surgical specimens by
western blotting. The middle weight neurofilament pro-
tein, NF-M, was detected in two specimens but was not
detected or barely detected in two others (Fig. 1G). This
protein normally is expressed in brain only in post mitotic
neurons, which might suggest the presence of some neu-
rons in 2 of the surgical samples. However, differentiated
neuronal marker expression has been reported in GBMs
previously [53-55] and NF proteins can be expressed in
non-neuronal brain tumors [56]. Thus, we do not know
which of the above possibilities occurred, but the NF-M
expression could be by glioma cells themselves in the
samples. Nonetheless, any neuronal inclusion within our
glioma surgical samples is likely scant, at best, based on
the abundance of GFAP staining (Fig. 1A).
Because L1 proteolysis was not apparent in fresh surgical
samples (Fig. 1E), two samples were dissociated and
placed in culture. Western blot analysis of cell culture
supernatant using the anti-ectodomain antibody (UJ127)
clearly showed the presence of the ectodomain fragment
from sample # 21 (Fig. 1H). The soluble L1 from these
cells was slightly lower in molecular weight than the cell
surface L1 from QT6 cells transfected with a human L1
expression plasmid. Thus, some surgical high-grade gli-
oma cells are able to proteolyze and release the L1 ectodo-
main, at least in culture.
L1 in glioma cell lines is proteolyzed
L1 expression and L1 proteolysis in glioma cell lines were
tested using reverse transcription-polymerase chain reac-
tion (RT-PCR), western blot, immunofluorescent stain-
ing, and flow cytometry (FACS) analysis. RT-PCR was
used with primers spanning the transmembrane region
and detected L1 mRNA in variants of rat C6 and 9L glioma
lines including C6, C6/LacZ, C6/LacZ7, 9L/LacZ, and 9L/
NgCAM cell lines (Fig. 2A). Rat glioma cell lines C6, C6/
LacZ, C6/LacZ7, 9L/NgCAM, 9L/LacZ exhibited the 461
bp band after RT-PCR. Rat brain (RB) served as a positive
control for L1 mRNA expression.
Western blot analysis was used to confirm L1 protein
expression in two of the above rat glioma cell lines and a
human glioma line U-87/LacZ (Fig. 2B). This analysis
demonstrated proteolysis in all three cell lines analyzed,
however, the patterns of proteolysis differed in each cell
line. In C6/LacZ7 cells the NCAM-L1 antibody detected
the 220 kDa surface full length L1, but 9L/LacZ and U-87/
LacZ cells exhibited high molecular weight bands that
were smaller than the full size L1 (Fig. 2B left panel). All
three cell lines exhibited the approximate 32 kDa trans-
membrane and cytoplasmic fragment resulting from L1
ectodomain shedding by ADAM proteolysis. However,
the additional lower weight bands in extracts from 9L/
LacZ and U-87/LacZ cells indicates that further, but dis-
tinct, proteolysis occurred in these cells; additional lower
weight bands were not always consistent (see Fig. 5B for
9L/LacZ). This suggests additional proteolysis of the L1
ectodomain, possibly by plasmin [57]. Surprisingly, anti-
body UJ127 detected a band approximately the size of full
length L1 in U-87/LacZ cell line (Fig. 2B right panel).
Since the NCAM-L1 antibody did not detect full length
membrane-bound L1 (200-220 kDa) in U-87/LacZ cells,
the high molecular weight band detected using UJ127
must be the full size ectodomain (approx. 190 kDa) after
ADAM10 cleavage, which runs at approximately the same
size on our gels. Taken as a whole, significant proteolysis
of L1 occurred in our three glioma cell lines that was
undetectable in the surgical samples.
Cell lines C6, 9L/LacZ and U-87/LacZ were immunofluo-
rescently stained on coverslips for L1 using a polyclonal
antibody, which targets the L1 ectodomain (Fig. 2C;Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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Figure 2 (see legend on next page)Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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Lagenaur; [58]). This antibody did not detect surface L1 in
C6, 9L/LacZ or U87/LacZ, however a strong punctate cyto-
plasmic staining of L1 was observed in fixed and perme-
ablized cells (top panels). No cell surface staining was
evident even when using a 60× oil immersion objective
lens (N.A. = 1.4). As a positive control, this antibody did
detect robust cell surface L1 in live mouse L1-transfected
quail QT6 cells even at low power (Fig. 2C, rightmost top
panel), whereas no staining occurred in untransfected
QT6 cells (rightmost bottom panel). We also performed
immunostaining after growing cells in the protease inhib-
itor GM6001 at up to 100 μM, which is 10× the concen-
tration that inhibited cleavage of L1 by other workers in
other cancer cell lines. This did not result in the appear-
ance of surface staining (data not shown), which suggests
that L1 in these glioma cells is proteolyzed intracellularly
where the protease inhibitor does not have access.
Antibody NCAM-L1, which was raised against a C-termi-
nal region peptide sequence of L1, also detected only the
cytoplasmic L1 in fixed/permeablized U-87/LacZ cells
(Fig. 2C, lower left panel). These results indicate that pro-
teolysis events of L1 occur in glioma cells that are consist-
ent with proteolysis by ADAM family members and
plasmin. Interestingly, in U-87/LacZ cells after live stain-
ing using the Lagenaur antibody, a punctate staining was
observed on the level of the coverslips (Fig. 2C, lower
center panel). This is interpreted to be L1 containing exo-
somal vesicles that are released from these cells (see
below), which would be observable as bright immunopo-
sitive puncta, although we did not co-stain these for an
exosomal marker.
FACS analysis using the Lagenauer antibody also demon-
strated L1 expression as distinct peaks in fixed and perme-
ablized C6/LacZ and U-87/LacZ cells (Fig. 2D, left
graphs). However, little, if any, surface L1 was observed in
live cells (Fig. 2D, right graphs), as no primary negative
control cells and L1-stained cells exhibited the same or
nearly the same staining patterns. This analysis corrobo-
rates immunostaining of cells on coverslips above to dem-
onstrate L1 proteolysis events in C6/LacZ and U-87/LacZ
cells to the extent that little or no L1 resides on the surface
of these cells. Overall, our data collectively show that L1
expression occurs in the glioma cell lines examined and
that L1 is extensively proteolyzed in those cells as well.
L1 is a component of exosomes
An established exosome isolation protocol [59] was used
to isolate exosomes from C6/LacZ, 9L/LacZ, and U-87/
LacZ glioma cell line culture media. At the end of multiple
rounds of centrifugation, the exosome pellet was resus-
pended in PBS/PI and analyzed by western blotting for the
presence of L1. L1 was detected in exosomes from all 3 gli-
oma cell lines, although the patterns were different from
corresponding cell extracts. Antibody UJ127, which is spe-
cific for human L1, detected full length L1 in exosomes
from U-87/LacZ cells (Fig. 3A) but expectedly not from
the two rat cell lines. In all three cell lines, the presence of
L1 was found in exosomes using the NCAM-L1 antibody
(Fig. 3B). However the small membrane/cytoplasmic frag-
ment remaining after ectodomain shedding was found
only in U87/LacZ cell exosome preparation. A cell extract
and exosome preparation from human breast cancer cell
line MDA-MB-435 served as a positive control for L1
detection in cells and exosomes (based on unpublished
L1 is expressed and proteolyzed in glioma cell lines Figure 2 (see previous page)
L1 is expressed and proteolyzed in glioma cell lines. (A) RT-PCR was performed on glioma cell lines to detect L1 
mRNA. PCR primers were designed as described to generate a 461 bp L1 PCR product. Rat glioma cell lines C6, C6/LacZ, C6/
LacZ7, 9L/NgCAM, 9L/LacZ exhibited the 461 bp band after RT-PCR. Rat brain (RB) served as a positive control for L1 mRNA 
expression. No-reverse transcriptase control reactions were run for every sample, and bands were not present in those lanes 
(not shown). (B) Western blot analysis of L1 expression. NCAM-L1 antibody (left panel) recognized L1 in rat glioma cell line 
9L/LacZ, C6/LacZ7, and human glioma U87/LacZ cells and resulted in lower than full length bands. The approximate weight 32 
kDa band indicates proteolysis by ADAM10 in all 3 cell lines. Further proteolysis in 9L/LacZ and U-87/LacZ cells is indicated by 
additional bands of lower than 200 kDa. Plain quail QT6 and mouse L1-expressing QT6 cells were used as negative and positive 
controls, respectively. Antibody UJ127 (right panel) against human L1 ectodomain was used for analysis of L1 in U87/LacZ 
human glioma cell line to determine if the complete ADAM10 ectodomain cleavage product was present, and the large frag-
ment (approx. 220 kDa) indicates its presence. (C) Rat glioma cell lines C6, 9L/LacZ and the human glioma cell line U87/LacZ 
were immunostained on coverslips with anti-L1 antibodies. Lagenaur polyclonal and NCAM-L1 revealed bright punctate intrac-
ellular staining for L1 in fixed and permeablized cells in all 3 cell lines but surface staining was not detectable. Small punctate 
staining could be visualized on the level of the coverslip outside the cell boundaries when U87/LacZ cells were stained live 
using Lagenaur (lower middle-left panel). The lower middle-right panel is a higher magnification of upper right panel. The two 
rightmost panels show quail QT6 transfected with mouse L1 cDNA (top right) or untransfected QT6 (bottom right) immunos-
tained live with the Lagenaur polyclonal antibody, with 3 bright surface stained transfected cells (top right). (D) FACS analyses 
of fixed (left two panels) and live (right two panels) cells. Fixed and permeablized cells exhibited distinct positive peaks of L1 
immunofluorescence compared to no-primary control cells. However, live cells exhibited nearly identical fluorescence profiles 
to the no-primary control cells indicating little, if any, cell surface L1.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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data; manuscript in preparation). The cell extract resulted
in robust full length and cytoplasmic fragment staining,
and the exosome preparation resulted in staining similar
to that from U-87/LacZ cells using the UJ127 antibody
and to that from C6/LacZ and 9L/LacZ cells using the
NCAM-L1 antibody. Exosome preparations were also
evaluated for the exosomal marker protein TSG101, and
each showed the presence of this marker (Fig. 3C). This
analysis showed that L1 can be released from glioma cells
as a component of exosomes, which suggests that exo-
somes might serve as another source of soluble L1 in
extracellular space to interact with glioma cell surface
integrins.
L1-binding integrins are expressed in glioma cell lines
The RGD motif within the 6th Ig domain of L1 ectodo-
main can be recognized by several RGD-binding integrins
on the cell surface. Here, one of the L1-binding integrins,
αvβ5, was examined in the three glioma cell lines. 9L/
LacZ cells were immunofluorescently stained live on cov-
erslips to visualize cell surface staining for αvβ5 (Fig. 4A).
These cells exhibited clear cell surface staining, which was
most prominent at cell edges. 9L/LacZ, C6/LacZ, and
U87/LacZ were also immunostained live in suspension
for quantitation of αvβ5 by FACS analysis (Fig. 4B). All
three cell lines exhibited distinct positive peaks for
integrin αvβ5 (blue lines) compared to no primary anti-
body negative controls (red lines), and U87/LacZ cells
appeared to have two different positive populations. This
would represent one high-level positive population and
another low-level positive population. Thus, this evidence
of the L1-binding integrin present in these gliomas cell
lines, along with L1 ectodomain proteolysis, indicates
that the RGD-containing ectodomain of L1 could stimu-
late glioma cell motility by triggering cell signaling path-
ways by interacting with L1-binding integrins.
Antisense-L1 retroviral vector decreased cell motility in 9L/
lacZ cells
An antisense-L1 retroviral vector was constructed to target
the first 530 bp of L1 including the L1 translation start
codon in order to attenuate L1 expression in infected cells,
similarly to our studies using retroviral antisense
sequences targeted to integrin subunits [60,61]. The anti-
sense sequence is located after the EGFP sequence, which
generates an antisense mRNA "tail" after EGFP. This
allows the antisense mRNA to attenuate L1 translation
and at the same time allows EGFP expression. 9L/LacZ rat
glioma cells were infected with either the antisense-L1-
GFP vector or control GFP vector. Because infections of
cell cultures were incomplete (approximately 50%), the
infected cells were sorted by FACS for GFP fluorescence to
increase percentages of GFP-positive infected cells. FACS
sorting resulted in 96% GFP vector infected cells (9L/GFP
cells) and 87% antisense-L1-GFP infected cells (9L/ASL1)
L1 is present in exosomes Figure 3
L1 is present in exosomes. Rat and human glioma cells 
were cultured in serum-free media overnight and the media 
was put through 3 rounds of centrifugation as described to 
isolate exosomes. The resulting pellets were resuspended 
and analyzed by western blot with anti-L1 antibodies UJ127 
and NCAM-L1. Full-length L1 was detected in exosomes 
released only from U87/LacZ human glioma cell line using 
UJ127 (A), whereas smaller weight proteolyzed forms were 
detected in exosomes from all 3 cell lines using NCAM-L1 
(B). The 32 kDa transmembrane fragment was detected only 
in U-87/LacZ exosomes (B). A cell extract (435 CE) and exo-
some preparation (435 Ex) from human breast cancer cell 
line MDA-MB-435 served as a positive control for L1 detec-
tion in cells and exosomes. Exosome preps were analyzed 
for exosomal marker Tsg101 as well as for L1 in (C). Each 
exosome preparation showed the predicted 45 kDa band for 
TSG101.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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based on GFP fluorescence (Fig. 5A). Western blotting was
used to evaluate attenuation of L1 expression in the anti-
sense vector infected and sorted 9L/LacZ cells. The NCAM-
L1 antibody was used to detect the 32 kDa L1 transmem-
brane/cytoplasmic domain and quantitation was per-
formed. Compared to GFP vector infected cells (9L/GFP),
the antisense-L1-GFP infected cells (9L/ASL1) were
reduced in L1 levels by approximately 90% (Fig. 5B).
After confirming that L1 expression was significantly
decreased in L1 antisense vector-infected cells, quantita-
tive motility analyses were performed using time-lapse
microscopy of cells along the edges of scratches made in
confluent monolayer cultures (Super Scratch Assay; [62]).
Cells infected with the antisense-L1-GFP vector migrated
into the "wound" at a lower average velocity throughout
the experiment (Fig. 5C) and significantly reduced overall
average velocity (0.381 μm/min.) compared to cells
infected with the GFP vector (0.253 μm/min.; 34% reduc-
tion; p < 0.001) (Fig. 5D). Overall average velocity meas-
urements are the averages of the velocities of 20 cells at 15
minute intervals over 23 hours, resulting in the average of
approximately 1800 velocity values for each condition.
These results show that the antisense L1 vector, which
decreased L1 expression in 9L/LacZ cells, significantly
decreased cell motility rates as well. The slower motility
rate of L1-attenuated cells suggests that it was the released
soluble L1 ectodomain and/or released L1 containing exo-
somes that stimulated their motility above their basal
level in an autocrine fashion.
Anti-L1 antibodies decreased cell motility
As an alternative method to inhibit L1 autocrine stimula-
tion of motility, antibodies specific for the rat L1 ectodo-
main (ASCS4; [63,64]) and an antibody specifically
targeting the L1 RGD motif in the 6th Ig domain (EZ1; see
Methods) were used with 9L/LacZ rat glioma cells in the
Super Scratch assay. Quantitation of cell motility was
determined after time-lapse microscopy as described. The
average cell velocities over time of treated vs. untreated
cells and the 3rd order polynomial curves of best fit were
plotted for the course of the experiment (Fig. 6A). The
velocity of 9L/LacZ cells in the culture containing ASCS4
was consistently reduced throughout the time course of
the experiment. The overall average velocity of 9L/LacZ
cells incubated with ASCS4 was decreased substantially
and significantly compared to the untreated control cells
(34%; p < 0.001; Fig. 6B), and similarly to cells with atten-
Figure 4
L1-binding integrin expression Figure 4
L1-binding integrin expression. (A) 9L/LacZ cells were 
immunostained live with a mouse monoclonal antibody 
against integrin αvβ5 (green) and nuclei were counterstained 
with bisbenzimide (blue). Cell surface staining for integrin 
αvβ5 is clearly visible. (B) Rat glioma cells 9L/LacZ and C6/
LacZ and human glioma cells U87/LacZ were immunostained 
live for integrin αvβ5 and analyzed by flow cytometry. All 3 
cell lines exhibited distinct positive peaks for integrin αvβ5 
(blue lines) compared to no primary antibody negative con-
trols (red lines), and U87/LacZ cells appeared to have two 
overlapping positive populations: one high-level positive pop-
ulation and another lower-lever positive population.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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uated L1 above. Overall average velocity measurements
were the averages of the velocities of approximately 20
cells at 5 minute intervals over approximately 20 hours,
resulting in the average of approximately 4800 velocity
values for each condition. The overall average velocity of
9L/Lacz cells incubated with EZ1 also was decreased sim-
ilarly and consistently (Fig. 6C, red), which resulted in an
overall decrease in motility of 32% (Fig. 6D; p < 0.001).
Overall average velocity measurements were the averages
of the velocities of approximately 40 cells at 5 minute
intervals over approximately 20 hours, resulting in the
average of approximately 9600 velocity values for each
condition. In contrast, we have performed time-lapse
motility experiments using the Lagenaur polyclonal anti-
body, and no decrease in motility was observed (data not
shown), which suggests that it binds to the L1 ectodomain
at a non-critical domain. Since 9L/LacZ cells do not
express surface L1 (Fig. 2; and [65]), ASCS4 and EZ1 acted
most likely through blocking the soluble L1 ectodomain
and/or exosomal vesicle interaction with integrin recep-
tors and, thus, interfering with autocrine stimulation of
motility.
The L1 peptide used to generate EZ1, containing the RGD
motif of L1, was also used to treat cells to antagonize the
binding of soluble L1 with integrins on the cell surface in
the Super Scratch assay. The peptide also decreased the
motility of 9L/LacZ cells consistently, but less than the
EZ1 antibody (Fig 6C, green). The overall average cell
velocity was decreased by 19% (Fig. 6D, green; p < 0.001).
Overall average velocity measurements were the averages
of the velocities of approximately 40 cells at 5 minute
intervals over approximately 20 hours, resulting in the
average of approximately 9600 velocity values. The ability
Figure 5
L1-attenuated glioma cells were less motile Figure 5
L1-attenuated glioma cells were less motile. (A) 9L/
LacZ cells were infected with mouse antisense-L1 retroviral 
vector or control pLEGFP-C1 vector. The positively infected 
cells were then sorted by FACS. Post-sort analysis of live 
cells is shown with fluorescence intensity level displayed 
along the X-axis. The black peak represents uninfected cells, 
the blue line represents pLEGFP-C1 vector infected negative 
control cells (96% infected), and the red line represent the 
cells infected with antisense-L1 vector (87% infected). Anti-
sense-L1 infected cells were less bright green than the 
extremely bright control GFP-only cells, presumably because 
of fusion of GFP to the antisense sequences. (B) L1 expres-
sion was analyzed by western blot in vector infected 9L cells 
purified above. Whole cell lysates were made and the same 
amount of total protein was loaded into each lane (30 μg). 
Western blots were stained with NCAM-L1 polyclonal anti-
cytoplasmic L1 and the density of the 32 kDa cytoplasmic L1 
fragment was analyzed using Un-Scan-It software. The 32 
kDa cytoplasmic fragment was reduced by approximately 
90% in the antisense infected 9L/ASL1 cells compared to the 
9L/GFP negative control cells. Blots were probed for 
GAPDH, which was used to normalize protein levels for 
quantitation of L1. (C) Cells were assessed by the Super 
Scratch assay for effects on cell motility. Antisense-L1 
infected 9L/lacZ cells showed decreased motility (red graph) 
compared to pLEGFP infected control cells (blue graph). The 
time-lapse graph shows the average velocities (thin lines) and 
3rd order polynomial best-fit curves (thick lines) of control 
and antisense-L1 infected populations of cells analyzed above 
at 15 min. intervals. The average velocity of the antisense-
infected cells was consistently lower throughout the time 
course of the experiment. (D) The overall average velocities 
were calculated using all individual cell velocities collected 
during the course of the experiment and graphed as single 
values for the two populations of cells. Control GFP-only 
infected cell velocity was 0.381 ± 0.012 s.e.m. and AS-L1 
infected cell velocity was 0.253 ± 0.008 s.e.m. The differences 
in the velocities are highly significant (p < 0.001). The experi-
ment was repeated twice with similar results.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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of the soluble L1 peptide to significantly inhibit motility
was not surprising and provides further evidence that L1
stimulates glioma cell motility, primarily through the sol-
uble ectodomain and/or L1-containing exosomes.
Discussion
In our study, L1 (L1CAM; CD171) expression was docu-
mented in high-grade human glioma surgical samples and
proteolyzed L1 ectodomain was released into the media
when these cells were cultured. Glioma cell lines from two
different species (rat and human) also expressed L1, and
proteolysis occurred most likely by ADAM10 to release a
large ectodomain. L1-binding integrins also were detected
in those cells, which raised the possibility that an auto-
crine stimulatory mechanism could be operating. Glioma
cell motility was reduced by using antisense retroviral vec-
Anti-L1 antibodies and RGD peptide inhibit glioma cell motility Figure 6
Anti-L1 antibodies and RGD peptide inhibit glioma cell motility. (A) Anti-L1 antibody ASCS4 was added to 9L/LacZ 
cultures and assessed by the Super Scratch assay for effects on cell motility. The time-lapse graph shows the average velocities 
and best-fit curves of the control and antibody treated 9L/Lacz cells over a 20 hour time period (15 cells each condition). The 
antibody ASCS4 consistently lowered the velocities of migrating cells throughout the course of the experiment. (B) The overall 
average velocities were calculated using all individual cell velocities collected during the course of the experiment and graphed 
as single values for the two populations of cells. Control cell velocity was 0.073 ± 0.002 μm/min. Velocity of the ASCS4 treated 
cells was reduced 34% compared to untreated controls at 0.048 ± 0.001 μm/min (p < 0.001). Bars are s.e.m. (C) Anti-L1 anti-
body EZ1 or the RGD-containing peptide antigen were added to cell cultures as described and assessed by the Super Scratch 
assay for effects on 9L/LacZ cell motility. The time lapse graph shows the average velocities and best-fit curves of the control, 
antibody treated, and peptide treated 9L/Lacz cells over a 20 hour time period (2 areas of interest and 40 cells each condition). 
The antibody EZ1 and peptide consistently lowered the velocities of migrating cells throughout the course of the experiment, 
with the antibody having a greater effect on reducing migration velocity. (D) The overall average velocity for the three popula-
tions of cells from (C) is shown. Control cell velocity was 0.214 ± 0.003 μm/min. Velocity of the EZ1 treated cells was reduced 
32% (0.146 ± 0.003 μm/min) and velocity of peptide treated cells was reduced by 19% (0.174 ± 0.003 μm/min) compared to 
untreated controls (p < 0.001 for each comparison). Bars are s.e.m. Shown are data from one representative experiment. The 
experiments were repeated twice with similar results.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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tor attenuation of L1 expression and blocking antibodies
against the L1 ectodomain. These experiments provide
evidence that in these glioma cells L1 is cleaved and
released to stimulate cell motility through an autocrine/
paracrine mechanism.
Malignant glioma is the most common human brain can-
cer [1]. The most aggressive type of glioma is glioblastoma
multiforme (GBM), which can kill patients within
months [66]. Although metastasis outside the CNS is rare
among GBM, the cancer is extremely invasive and can
migrate rapidly inside the brain. Previous studies by oth-
ers showed L1 expression in some glioma cell lines and
primary glioma, and it has been suggested that L1 facili-
tates glioma cell migration within the brain [4,46-48,67].
However, L1 proteolysis needed to be characterized and
quantitative experiments needed to be performed to test
the hypothesis that L1 facilitated glioma cell motility by
an autocrine/paracrine mechanism.
Our study confirmed and considerably extended previous
studies on expression and proteolysis of neural adhesion
molecule L1 in high-grade human glioma surgical sam-
ples and in rat and human glioma cell lines by using RT-
PCR, western blotting, immunofluorescent staining, and
FACS analysis. L1 was detected in 17 out of 18 surgical
samples analyzed. This suggests that L1 may be a marker
for high-grade gliomas and that it may play a significant
functional role in the behavior of these cells. However, by
western blot analyses of primary surgical specimens we
could not detect that L1 was proteolyzed to generate an
autocrine stimulatory ectodomain, in contrast to the pro-
teolysis that occurred in cell lines. This might be because
our samples were from the interior of the tumor, not the
margin, where the cells are densely packed and no free
edge exists where the cells are invading the brain. L1 and
its protease ADAM10 have been shown in colon cancer
only at the invasive front [31], where proteolysis occurs to
stimulate cell migration. We did detect L1 ectodomain in
culture supernatant from surgical specimen cells. It is pos-
sible that gliomas are similarly autocrine stimulated by
proteolyzed L1 ectodomain only at the tumor margin or
when cells are not in a dense tumor mass such as in cul-
ture. However, control mechanisms may be different since
active ADAM10 was expressed in all of our surgical sam-
ples, albeit only at a high level in one sample (# 10).
Either the levels of active ADAM10 were not sufficient in
the surgical samples to generate detectable L1 ectodo-
main, or L1 proteolysis was inhibited, possibly by its
inclusion in intercellular junctions [68] in the interior of
the tumor mass. At this time, the lack of L1 ectodomain in
the surgical samples along with active ADAM10 requires
further investigation.
L1 could only be visualized intracellularly in fixed glioma
cell lines, with surface staining lacking in both live and
fixed cells by immunocytochemistry and FACS analysis.
These results suggested the cleavage of surface L1 by its
known surface protease, ADAM10 [35], to release the sol-
uble L1 ectodomain. The cell surface L1-binding integrin
αvβ5 was found on the three glioma cell lines used here.
This integrin previously was shown to interact with L1 and
to be involved in L1-enhanced cell migration [33].
Integrin αvβ5 detection in the cell lines indicates the pos-
sibility that soluble L1 ectodomain could interact with
this integrin receptor.
L1 ectodomain stimulation in glioma cells was demon-
strated by using a highly quantitative time-lapse motility
assay [62,65], which allowed tracking of individual cell
migration distances and velocities throughout the experi-
ment. Motility decreased significantly when an antisense
retroviral vector was used to attenuate overall L1 expres-
sion in 9L/LacZ cells. We have used this antisense strategy
previously with success to attenuate integrin subunits in
normal neuroblasts in developing brain and to implicate
them in neuronal migration [60,61]. Since there is no sur-
face L1 on these cells, this strategy along with the antibody
blocking experiments to sequester the soluble L1 ectodo-
main, provides evidence that an autocrine stimulation of
motility occurs in these glioma cell lines. Our collective
results demonstrated that the soluble L1 ectodomain, and
not surface L1, stimulated cell motility in glioma cell
lines. This suggests that autocrine/paracrine stimulation
by the soluble L1 ectodomain might be a mechanism that
operates during pathologic diffuse glioma cell migration,
for which a mechanism has still not been elucidated.
Our findings are different from those of Senner et al.
(2002) [69] where they found no intrinsic L1 expression
in their C6 rat glioma cell line. In our studies, the C6 cell
line and its two derivatives (C6/lacZ and C6/LacZ7) not
only expressed L1, but also proteolyzed it, presumably by
ADAM10. We suppose that either their cultures of C6 cells
lost L1 expression as a whole, the cell clone they picked
was a non-expressing variant of L1 expression, or that
their inability to detect L1 was a result of their antibody
choice. We have found that the several different anti-L1
antibodies we used are individually suited for particular
assays, and none are best for all. Thus, their findings that
ectopic expression of L1 in C6 cells resulted in no signifi-
cant difference in migration on either matrigel or myelin
compared to plain C6 cells might be because the cells
already expressed L1, but they did not detect it. It is
equally possible that our particular cultures of C6 and
derivatives actually do differ in L1 expression from their
particular cultures, for unknown reasons. Nonetheless,
our C6 cell lines were found to express intrinsic L1 and to
cleave it.Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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Previously, we found that C6 cell motility was signifi-
cantly decreased when those cells were plated on cell
monolayers that ectopically expressed a non-cleaved cell
surface NgCAM/L1 (3T3/NgCAM cells; [62]). Thus, their
autocrine stimulation by intrinsic L1 ectodomain
appeared to be overridden by heterophilic adhesive inter-
actions between the extrinsic NgCAM on the 3T3 cell sur-
faces, presumably with integrin receptors. In addition,
ectopic expression of cell surface NgCAM/L1 directly in
9L/lacZ cells, which we have shown here also express and
cleave intrinsic L1, decreased their motility significantly
[65], which suggests that surface L1 is not stimulatory
even on a background of cleaved L1. In all, these experi-
ments suggest that L1 is stimulatory for motility only
when predominantly cleaved to form a soluble ectodo-
main. However, when also present in the uncleaved cell
surface form it reduces motility due to adhesive interac-
tions that override any stimulatory effect of the ectodo-
main. Thus, we propose a model whereby for high-grade
glioma cells to migrate away from the tumor mass and to
be invasive, they must proteolyze L1 to cause autocrine
stimulation. Otherwise, the cells would be strongly adher-
ent via their cell surface L1-L1 and L1-integrin interac-
tions.
Conclusion
Our novel results support a model of autocrine/paracrine
stimulation of cell motility in glioma cells by a cleaved L1
ectodomain and/or released exosomal vesicles containing
L1. This mechanism might explain the diffuse migratory
behavior of high-grade glioma cancer cells within the
brain, where they apparently do not follow discernable
anatomical structures. We found L1 in a high percentage
of high-grade glioma surgical specimens and shed L1 ecto-
domain in their cell culture, which suggests a potential
function in these cells. Established glioma cell lines
expressed and proteolyzed L1 to release a soluble ectodo-
main and also released minute exosomal vesicles that
contained L1, both of which could serve as diffusible
sources of L1 that stimulate the migration of these cells in
an autocrine/paracrine manner. Cell lines also expressed
an L1-binding integrin receptor, which could mediate
necessary intracellular signaling events. Functional studies
confirmed that L1 expression and ectodomain release was
responsible for increased glioma cell motility.
Methods
Primary glioma surgical samples and cell lines
A total of 18 high-grade (Grade III and GBM) human pri-
mary glioma surgical samples were obtained through the
Tissue Procurement Center at the Helen F. Graham Cancer
Center, Christiana Care (Newark, DE) following approved
protocols and analyzed by western blotting for L1 expres-
sion. The surgical samples were transported in Hibernate
A medium (BrainBits LLC, Springfield, IL) on ice. The
samples were washed in ice-cold neurobasal medium
(Invitrogen, Carlsbad, CA), the visible necrotic sites of the
tumor were trimmed, and the remaining tissue was cut
into <1 mm3 pieces. Pieces from 14 surgical samples were
lysed directly in RIPA lysis buffer (150 mM NaCl, 1% TX-
100, 1% SDS, 0.5% sodium deoxycholate, 50 mM Tris pH
7.5) with Complete Mini EDTA-Free Protease Inhibitor
cocktail tablets (PI) (Roche Diagnostics, Indianapolis, IN)
followed by sonication for western blot analysis. Pieces
from 4 surgical samples were rinsed in neurobasal
medium and then incubated at 37°C in 5 ml of 0.25%
trypsin-EDTA (Mediatech Inc., Herndon, VA) before sam-
ple dissociation into single cells. The enzymatic digestion
was terminated by 5 ml of 0.03% SBTI (Soybean Trypsin
Inhibitor) and 0.003% DNase I on ice for 10 minutes
before the sample was centrifuged. The supernatant was
removed after centrifugation and 2 ml of SBTI/DNase was
added to resuspend the pellet. Single cells were dissoci-
ated by trituration with a Pasteur pipet. The cells were col-
lected in the supernatant after waiting for 5 minutes on ice
to let the non-dissociated tissue pieces sink to the bottom
of the tube. Dissociated cells were pelleted by centrifuga-
tion and then were cultured in DMEM (Mediatech, Inc.,
Herndon, VA) with added 10% fetal bovine serum (FBS;
Hyclone, Waltham, MA), 2 mM L-glutamine (Mediatech
Inc.), and penicillin-streptomycin (Mediatech Inc.). Cell
cultures were maintained for 2, 4, and 15 weeks before
trypsinization from the culture plates and preparation of
samples for western blot analysis for L1 as above. The cells
were growing in the culture medium with PI overnight
before the medium was collected and filtered through 0.2
μm filter. Then, the filtered cell culture supernatant was
further concentrated using a YM-100 protein concentrator
(Millipore, Billerica, MA). Some pieces of glioma surgical
samples were fixed in 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA) in PBS at room tem-
perature after trimming. The fixed samples were cryopro-
tected in 30% sucrose in PBS overnight at 4°C and were
frozen in tissue freezing medium (Triangle Biomedical
Sciences Inc, Durham, NC) in an ultralow freezer (-75°C).
The tissue sections were cut at 10 μm thickness on a Leica
cryostat and used for immunofluorescent staining below.
Glioma cell lines used in this study were obtained from
the American Type Culture Collection (ATCC, Manassas,
VA). 9L/LacZ is a rat gliosarcoma cell line [70]. C6/LacZ,
C6/LacZ7 [71], and C6 are rat glioma cell lines [72]. U-87/
LacZ is a human GBM cell line obtained and described
previously [65]. QT6 is a quail fibrosarcoma cell line [73].
CHO is a Chinese hamster ovary cell line [74]. QT6 cells
were cultured in Medium 199 (Mediatech, Inc.) with 5%
FBS, 20% tryptose phosphate broth, 2 mM L-glutamine
and penicillin-streptomycin. Other cell lines were cul-
tured in DMEM (Mediatech, Inc.), 10% BGS (bovine
growth serum; Hyclone, Waltham, MA), 2 mM L-Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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glutamine, and penicillin-streptomycin and incubated at
37°C with 5% CO2.
Vectors, transfection and infection
QT6 cells were transfected with a full length mouse L1
expression plasmid with an RSV promoter, LacZ gene and
IRES-L1 (1481dL1Nco) or human L1 expression plasmid
using standard calcium phosphate transfection method
[75]. Transfected cells served as a positive control for L1
expression in western blotting. CHO cells were infected
with a lentiviral vector (1879hL1ecto) containing a CMV
promoter followed by the complete human L1 ectodo-
main sequence and served as positive control for detecting
human L1 ectodomain.
The mouse L1 antisense retroviral vector was generated
with a pLEGFP-C1 expression vector (Clontech, Moutain
View, CA). pLEGFP-C1 facilitates retroviral delivery and
expression of the enhanced green fluorescent protein
(EGFP) or carboxy-terminal fusions of EGFP to a protein
of interest. The retroviral elements in pLEGFP-C1 are
derived from a Moloney murine leukemia virus (MoM-
uLV). The antisense sequence is targeting the first 530 bp
of mouse L1 cDNA [76] including the start codon of L1
protein translation. The PCR product was generated using
the forward primer: 5'-CGG CGG GTC GAC CCT TTG
AAA AAC ACG ATG ATA AGC TTG CCA CAA-3' and the
reverse primer: 5'CGG CGG AGA TCT GTT TGA TGT CGA
AAA TCT TGC TGT TCA TCC AGT-3'. The double CGG are
the overhangs designed for easier cloning. GTC GAC is
SalI restriction site, AGA TCT is BglII restriction site. Both
restriction enzyme sites were used for ligating the anti-
sense L1 sequence into pLEGFP-C1 multiple cloning sites.
The antisense sequence is located immediately following
the EGFP stop codon, which generated a mouse L1 anti-
sense mRNA "tail" after EGFP transcription. In this way,
the "tail" can serve as antisense mRNA to attenuate L1
protein expression, and at the same time it will not inter-
fere with EGFP expression. The vector (10 μg) was then
transfected into HEK 293T/17 cell line with the helper
plasmid pPAM (10 μg) using standard calcium phosphate
method; the viruses were collected 48 and 72 hours after
transfection. 9L/LacZ cells were infected with the viruses.
The pLEGFP-C1 vector was also transfected into HEK
293T/17 cell line to produce viruses. The 9L/LacZ cells
infected with empty pLEGFP-C1 viruses were served as
negative control. The positively infected 9L/LacZ cells
were sorted on a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA) for positive GFP fluorescence.
Antibodies for western blotting, immunofluorescent 
staining, time-lapse and FACS analysis
The antibodies used here are as follows. NCAM-L1 C-20
(cat. # sc-1508; Santa Cruz Biotechnology, Santa Cruz,
CA) is a goat polyclonal antibody raised against a peptide
mapping within a C-terminal cytoplasmic domain of
L1CAM of human origin. UJ127 (cat. # GTX72362; Gene
Tex, Irvine, CA) is a mouse monoclonal antibody raised
against the human ectodomain of L1 (within the
fibronectin repeats and close to the membrane region).
Lagenaur anti-L1 is a rabbit polyclonal antibody raised
against the whole L1 molecule and reacts with the ectodo-
main of mouse, rat and human L1 [77], and was gener-
ously provided by Dr. Carl Lagenaur (Univ. of
Pittsburgh). ASCS4 (Developmental Studies Hybridoma
Bank, DSHB) is a mouse monoclonal anti-rat L1 ectodo-
main antibody [63,64]. It does not react with human L1.
EZ1 is a custom rabbit polyclonal antibody generated by
targeting a 15 amino acid human L1 peptide sequence
provided to EZBiolab (Westfield, IN). The peptide
sequence "QPSITWRGDGRDLQEC" was centered on the
integrin binding RGD sequence in the 6th Ig domain
(extracellular region). This was done for the purpose of
raising function blocking antibodies that compete with L1
ectodomain to interact with RGD-binding integrins in cell
migration assay. This sequence was found only in L1
when analyzed by BLAST (National Institutes of Health).
Anti-ADAM10 (cat. # 28071; AnaSpec, Inc., Fremont, CA)
was a rabbit polyclonal antibody. Mouse anti-human
integrin  αVβ5 (cat. # MAB2019Z; Chemicon Interna-
tional, Billerica, MA) was a mouse monoclonal antibody
which reacts with the human integrin αVβ5 and binds to
the ligand binding site. Several different loading controls
(GAPDH,  β-tubulin,  α-actin, and HSP70) were used.
None of these gave results consistent with the BCA assay
for surgical glioma specimens, and all resulted in different
strength bands relative to each other. This discrepancy was
not seen with the glioma cell lines, and we suspect that
none of these loading controls is more accurate than the
BCA assay for surgical gliomas, probably due to each load-
ing control marker being expressed variably in the differ-
ent surgical gliomas. The GAPDH antibody (cat. # 2118;
Cell Signaling, Boston, MA) is presented as the loading
control in this paper. The monoclonal mouse anti-
TSG101 antibody (4A10; cat. # ab83; Abcam, Cambridge,
MA) was used as the exosome marker. To detect GFAP, a
polyclonal rabbit anti-GFAP antibody was used (cat. # 18-
0063; ZYMED Laboratories, South San Francisco, CA).
Anti-NF-M (cat. # IMG-5076A-2; IMGENEX, San Diego,
CA), a polyclonal rabbit anti-neurofilament (recom-
binant) antibody, was used to detect medium neurofila-
ment in the surgical samples. To detect mitotic cells, a
rabbit polyclonal anti-Ki67 antibody (cat. # ab15580;
Abcam, Cambridge, MA) was used followed by Alexa
Fluor-594 secondary antibody. Secondary antibodies used
for L1 immunostaining were HRP-conjugated donkey
anti-goat IgG (Jackson Immunoresearch, West Grove, PA),
Alexa Fluor-488 or -594 donkey anti goat IgG (Molecular
Probes, Invitrogen, Carlsbad, CA), HRP-conjugated goatCancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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anti-mouse IgG (Jackson Immunoresearch), or Alexa
Fluor- 488 or -594 goat anti mouse IgG (Molecular
Probes, Invitrogen). For integrin receptor and live cell L1
immunostaining a biotin-conjugated goat anti-mouse or
anti-rabbit IgG (Jackson Immunoresearch) followed by
Alexa Fluor-488 streptavidin conjugate (Molecular
Probes, Invitrogen) were used.
RT-PCR
The total RNA was extracted from the cell lines using the
RNeasy Mini Kit (Qiagen, Valencia, CA). The first-strand
cDNA synthesis was carried out using the SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen).
The primer sequences used were designed against the
transmembrane domain of L1 conserved in both humans
and mice. The forward primer sequence was 5'-TACCGCT-
TCCAGCTTCAG and the reverse sequence was 5'-TGAT-
GAAGCAGAGGATGAGC. PCR Master Mix (Invitrogen)
was used and the reaction was carried out in a thermal
cycler (Techne, Burlington, NJ) using an initial denatura-
tion step for 15 min at 95°C, after which the reactions
were subjected to 40 cycles of amplification. Each cycle
consisted of denaturation for 30 seconds at 94°C, anneal-
ing for 30 seconds at 55°C and extension for 1 min at
72°C. The final extension was for 10 min at 72°C and the
final hold was at 4°C.
Western blotting
To make protein extracts, cells culture dishes were kept
cold on ice for 10 min and rinsed with cold PBS/PI (Phos-
phate buffered saline with protease inhibitors) before sol-
ublizing them in RIPA lysis buffer with PI for 2-3 min on
ice. The cells were then scraped, collected in microcentri-
fuge tubes and the lysates were clarified by sonication at
10% power using a Sonic Dismembrator (Model 500,
Fisher Scientific, Pittsburgh, PA). The primary human gli-
oma surgical samples were minced and put into RIPA lysis
buffer as explained previously; lysates were sonicated at
10% power as well. Protein quantification was performed
using the BCA Assay (Pierce Biotechnology, Pittsburgh,
PA). The samples were prepared by adding the NuPage 4×
LDS sample buffer (Invitrogen) and the NuPage 10×
reducing agent (Invitrogen), heating them at 70°C for 10
min and centrifuging them. Equal amounts of the pro-
teins (8-30 μg, depending on experiment) were loaded on
NuPage 4-12% gradient polyacrylamide gels (Invitrogen)
along with protein ladders (See Blue Plus 2 prestained
standard, Magic Mark XP, Invitrogen). A small volume
(500 μl) of the NuPage antioxidant (Invitrogen) was also
added to the top chamber of the running buffer tank
(OWL Separation Systems, Inc, Waltham, MA) prior to the
electrophoresis to prevent the proteins from reoxidizing
during electrophoresis. Running buffer used was the
NuPage MOPS running buffer (Invitrogen).
For Western transfer, polyvinylidine fluoride (PVDF)
membranes (0.45 μm, Invitrogen) were treated in metha-
nol for 30 sec- 1 min and rinsed with water in order to
make them hydrophilic. Transfer buffer used was the
NuPage 20× transfer buffer (Invitrogen) with 20% metha-
nol and 1.4 ml of the NuPage antioxidant. The transfer
was carried out at 4°C at 30 V overnight in a Fisher model
172538 transfer apparatus. The membrane was blocked in
the blocking solution (5% nonfat dry milk solution in
Phosphate Buffered Saline with 0.01% Tween20) rotating
or rocking for either 1-2 hours at room temperature or
overnight at 4°C. The blots were then incubated in the
primary antibody, either rocking for 1-2 hours at room
temperature or overnight at 4°C. HRP-conjugated second-
ary antibody was then added to the membranes and kept
on a rotator or rocker for 1 hour at room temperature. The
membranes were developed for 1 to 2 min using the
enhanced chemiluminescence detection system (Amer-
sham, Piscataway, NJ or Pierce Biotechnology, Pittsburgh,
PA); the protein bands in the blots were finally visualized
by exposing the Blue Basic Autorad Film (ISC Bioexpress,
Kensville, UT) for various time intervals.
Immunofluorescent staining
Fixed cell staining was carried out by growing cells on cov-
erslips previously coated with 200 μg/ml poly-L-ornithine
(Sigma-Aldrich, St. Louis, MO) and then first fixing them
in 1% formaldehyde in PBS for half an hour at room tem-
perature. The coverslips were then rinsed twice in PBS and
the cells were incubated in the primary antibody diluted
in PBS + 5% FBS or 5% normal goat serum + 0.03% Triton
X-100 for an hour at room temperature. The coverslips
were then rinsed twice with PBS and incubated in the
Alexa Flour 488 or 594 secondary antibodies (Molecular
Probes, Invitrogen) in the same diluents as the primary
antibodies for 45 min-1 hr at room temperature. The cov-
erslips were again rinsed in PBS and incubated in 10 μg/
ml bisbenzimide (Sigma-Aldrich) in PBS for 5-10 min.
The cells were rinsed again in PBS and the coverslips were
then mounted in 6 μl buffered glycerol/para-phenylenedi-
amine (pH 8.0) on glass slides. For live cell staining for L1
or integrin, instead of fixing the cells initially, cells were
incubated in primary antibody in DMEM + 5% heat-inac-
tivated FBS on ice, rinsed, fixed with 1% formaldehyde at
room temperature for 30 minutes, rinsed, incubated in
biotin-conjugated secondary antibody in PBS + 5% NGS,
rinsed, incubated in Alexa 488-streptavidin, and rinsed
before the nuclear staining and mounting. The staining
was visualized using a Nikon Microphot-FX microscope
with Fluor objectives.
FACS analysis
The cells were trypsinized lightly in 0.05% Trypsin/0.02%
EDTA for several minutes, resuspended in DMEM + 10%
H-I serum and centrifuged at 1000-1200 × g (700-800Cancer Cell International 2009, 9:27 http://www.cancerci.com/content/9/1/27
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rpm Beckman Allegra 6R centrifuge). The supernatant was
aspirated and the cell pellet was resuspended in DMEM +
10% H-I serum. For fixed cell L1 staining, the cells were
fixed first with 1% formaldehyde (as described above) fol-
lowed by Lagenaur anti-L1 primary and Alexa Fluor-488
secondary antibody incubation. For live cell staining for
L1 and integrins, cells were incubated with primary in the
heat-inactivated serum containing diluents on ice (as
described above), fixed, incubated in a biotin-conjugated
secondary antibody followed by Alexa Fluor-488 strepta-
vidin conjugate (Molecular Probes, Invitrogen). The cells
then were examined by a Becton Dickinson FACSCalibur
flow cytometer for immunofluorescence levels using Cell
Quest software.
Exosome isolation
Ultracentrifugation was performed to isolate the exo-
somes from the culture media of the glioma cell lines.
Briefly, the glioma cells were seeded on 10 cm dishes with
serum-containing media until 70-80% confluent. The
media was then removed and replaced with serum-free
media with PI. The cells were again incubated for 18-24
hours in order for the soluble L1 ectodomain and the L1-
containing exosomes to accumulate in the media. The
media was collected, filtered through a 0.2 micron filter to
remove cell debris. The filtered media was then put
through 3 rounds of centrifugation: 1,200 × g for 10 min-
utes, 10,000 × g for 20 minutes and 100,000 × g for 22
hours. The first two rounds of centrifugation were done
using the Sorvall RC-5B centrifuge with a SS-34 (fixed
angle) rotor mainly to further remove cell debris. The last
round of centrifugation was done at 4°C using Beckman
L8-55M Ultracentrifuge with a SW41 Ti (swinging bucket)
rotor. Following the ultracentrifugation, the supernatant
was removed and the glassy pellet that formed at the bot-
tom of the ultracentrifuge tubes, which was presumed to
contain exosomes, was resuspended in a small volume of
sterile PBS (40-100 μl) with PI. The exosomal samples
were analyzed by western blotting.
Scratch assay and time-lapse microscopy
Motility of 9L/LacZ cells infected with retroviral vectors
and incubated with anti-L1 antibodies was measured by
using time-lapse microscopy as previously described
[62,63]. Cells were grown to confluence either on 35 mm
glass bottomed dishes (MatTek Corp., Ashland, MA or
World Precision Instruments, Inc., Sarasota, FL) for 9L/
LacZ infected with mouse antisense-L1 and control retro-
viral vectors or on plastic tissue culture dishes for 9L/LacZ
cells incubated with anti-L1 antibodies. Monolayers were
"wounded" by introducing scratches with a sterile plastic
1 ml pipettor tip in serum-free media. For antibody block-
ing experiments, ASCS4 and EZ1 antibodies were added
as purified IgG to a concentration of 5 μg/ml and 40 μg/
ml, respectively and the RGD-containing L1 peptide was
added at 40 μg/ml. Cultures were then placed into a cus-
tom culture chamber mounted on a ProScan II automated
stage (Prior Scientific, Rockland, MA) on a Nikon TE-
2000E microscope. Temperature was maintained at 37°C
by a combination of a warm air temperature controller
(Air Therm, World Precision Instruments, Sarasota, FL)
and thermoelectric warming with an optically clear tem-
perature-controlled stage insert (Tokai Hit, Shizuoka-ken,
Japan). The atmosphere within the chamber was kept at
an average of 5% CO2/95% air using a gas injection con-
troller (Forma Scientific, Marietta, OH). A CoolSnap ES
CCD camera (Photometrics, Tucson, AZ) was used to cap-
ture images over the course of the experiment using a
Nikon Plan Fluor 20× ELWD objective at areas of interest
on each plate for approximately 20 h. Retroviral vector
experiments entailed collection of phase contrast and flu-
orescence images (488 nm illumination) at 15 min inter-
vals and antibody blocking experiments entailed
collection of phase contrast images at 5 min intervals. The
system was controlled using MetaMorph Premier Soft-
ware (Molecular Devices Corporation, Downingtown,
PA). Quantitative analysis of cell motility was performed
on acquired sequential phase contrast images using the
MetaMorph software "Track Points" feature with nucleoli
serving as imaging targets. Data were evaluated statisti-
cally using Student's two-tailed t-test and graphed using
Microsoft Excel.
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